PCM
FSTX

PenderFund Capital Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

PenderFund Capital Management’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22,760
Closed -$195K – 158
2022
Q4 		$195K Sell
22,760
-3,580
-14% -$19.8K 0.06% 100
2022
Q3 		$186K Buy
26,340
+3,390
+15% +$21.3K 0.06% 110
2022
Q2 		$185K Buy
+22,950
New +$77.3K 0.05% 98

PenderFund Capital Management's FSTX Position: Q1 2023 in Review

PenderFund Capital Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 22,760 shares — an estimated $195K sold.

PenderFund Capital Management first reported a position in FSTX in Q2 2022 and held it in 3 quarters. The position peaked at $195K in Q4 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • PenderFund Capital Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • PenderFund Capital Management sold 22,760 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $195K.
  • PenderFund Capital Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • PenderFund Capital Management's F-star Therapeutics, Inc. Common Stock position peaked at $195K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on PenderFund Capital Management's 13F filing for Q1 2023, filed 15 May 2023.